Vera Therapeutics (VERA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Key Insights
Critical company metrics and information
Share Price
$48.02Market Cap
$3.04 BillionTotal Outstanding Shares
63.32 Million SharesTotal Employees
82Dividend
No dividendIPO Date
May 14, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.veratx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-185.09 Million |
Net Cash Flow From Financing Activities | $305.55 Million |
Net Cash Flow From Financing Activities, Continuing | $305.55 Million |
Net Cash Flow, Continuing | $-185,000.00 |
Net Cash Flow From Operating Activities, Continuing | $-120.64 Million |
Net Cash Flow From Investing Activities, Continuing | $-185.09 Million |
Net Cash Flow | $-185,000.00 |
Net Cash Flow From Operating Activities | $-120.64 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations After Tax | $-134.38 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-134.38 Million |
Nonoperating Income/Loss | $10.91 Million |
Net Income/Loss | $-134.38 Million |
Income/Loss From Continuing Operations Before Tax | $-134.38 Million |
Operating Income/Loss | $-145.28 Million |
Diluted Average Shares | $54.12 Million |
Revenues | $0.00 |
Research and Development | $113.61 Million |
Net Income/Loss Attributable To Parent | $-134.38 Million |
Basic Earnings Per Share | $-2.61 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Expenses | $145.28 Million |
Basic Average Shares | $54.12 Million |
Other Operating Expenses | $31.67 Million |
Diluted Earnings Per Share | $-2.61 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity | $289.06 Million |
Other Non-current Assets | $4.06 Million |
Liabilities And Equity | $368.56 Million |
Fixed Assets | $368,000.00 |
Current Assets | $364.13 Million |
Wages | $3.64 Million |
Current Liabilities | $26.46 Million |
Accounts Payable | $4.60 Million |
Other Non-current Liabilities | $2.57 Million |
Long-term Debt | $50.47 Million |
Liabilities | $79.50 Million |
Assets | $368.56 Million |
Other Current Liabilities | $18.22 Million |
Noncurrent Assets | $4.43 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $289.06 Million |
Noncurrent Liabilities | $53.04 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.